Peptide Database

A small molecule inhibitor of NNMT enzyme that boosts metabolism and promotes fat cell apoptosis. Shows promise as a novel anti-obesity agent in preclinical research.

A naturally occurring nucleoside and potent AMPK (AMP-activated protein kinase) activator. Mimics the cellular effects of exercise by activating energy-sensing pathways. Studied for metabolic disease, exercise performance, fat oxidation, and cancer treatment.

A synthetic fragment of the C-terminus of HGH (amino acids 176-191) that retains the fat-burning properties of growth hormone without affecting blood sugar or IGF-1 levels.

A selective mitochondrial uncoupler that increases energy expenditure by diverting the proton gradient from ATP synthesis to heat production. In mouse models, BAM15 reversed diet-induced obesity and insulin resistance without increasing body temperature, heart rate, or affecting the plasma membrane — overcoming the critical safety limitations of earlier uncouplers like DNP.

A long-acting amylin analog being co-developed with semaglutide (as CagriSema) for obesity. Amylin signals satiety to the brain independently of GLP-1, making the combination synergistic for weight loss.

The original C-terminal fragment of human growth hormone spanning amino acids 176-191. Contains the fat-burning region of HGH without the growth-promoting (IGF-1-stimulating) region. Slightly different structure from AOD-9604 but essentially the same compound; AOD-9604 is a modified version with a disulfide bridge.

An FDA-approved once-daily GLP-1 receptor agonist for type 2 diabetes and weight management. Produces 5-8% average weight loss with established cardiovascular safety data.

A GLP-1 and glucagon receptor co-agonist developed by Innovent Biologics. In Phase 3 clinical trials in China with strong efficacy data. Shows comparable weight loss to tirzepatide while also reducing liver fat. Also studied for type 2 diabetes management.

A mitochondria-derived peptide that acts as a metabolic regulator, improving insulin sensitivity, exercise capacity, and potentially mimicking caloric restriction.

The first truly oral (tablet) GLP-1 receptor agonist that is a small molecule — not a peptide requiring oral protection like semaglutide (Rybelsus). Phase 3 trials showed 14.7% weight loss, close to injectable semaglutide. No needle required — once-daily pill with no food restrictions.

A synthetic pancreatic peptide bioregulator targeting pancreatic islet cell function. Normalizes insulin secretion, improves beta-cell function, and reduces pancreatic oxidative stress. Studied for type 2 diabetes prevention, metabolic syndrome, and pancreatic aging.

An emerging triple agonist targeting GLP-1, GIP, and glucagon receptors simultaneously. Phase 3 clinical trials show unprecedented weight loss of up to 24% body weight.

An FDA-approved GLP-1 receptor agonist that produces significant weight loss (average 14.9% body weight in clinical trials). One of the most clinically validated weight loss peptides available.

A pan-agonist of all three estrogen-related receptors (ERRα, ERRβ, ERRγ) that activates the same genetic programs triggered by endurance exercise. Mice given SLU-PP-332 showed 70% greater endurance capacity and significant fat loss without exercise.

A dual GLP-1 and glucagon receptor agonist developed by Boehringer Ingelheim. Phase 2b trials showed superior weight loss to semaglutide at 6 months. Also being studied for NASH/MASH (metabolic steatohepatitis), a liver disease with limited treatment options.

A serotonin-noradrenaline-dopamine reuptake inhibitor (SNDRI) originally developed for Parkinson and Alzheimer disease. In Phase 2 obesity trials, produced 12.8% weight loss over 6 months — more than twice that of approved weight loss drugs at the time.

A dual GLP-1 and GIP receptor agonist representing the next generation of metabolic peptides. Achieves greater weight loss than semaglutide with average reductions of 20-22.5% body weight.